Roflumilast: Clinical Trials

34 trials of Roflumilast, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

30 completed, 1 not yet recruiting, 1 recruiting, 1 terminated. 34 Phase 3, 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 334Completed 30, Not yet recruiting 1, Recruiting 1, Terminated 1, Unknown 1
Phase 24Completed 3, Not yet recruiting 1

Follow Roflumilast: new trials by email Literature Review of Roflumilast trials Research Report on Roflumilast

Trials (filtered) newest first · largest first

All 34 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Evaluating the Safety and Efficacy of Roflumilast in the Treatment of Nonalcoholic Fatty Liver Disease Patients
Placebo, Roflumilast - NAFLD (Nonalcoholic Fatty Liver Disease)
Phase 2 / Phase 3Not yet recruitingTanta University602026-11-012026-10-28
Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients
Fluoxetine, Roflumilast, Placebo - Depressive Disorder, Major
Phase 3RecruitingTanta University602025-03-012026-05-04
Roflumilast Versus Methotrexate in Psoriasis
Roflumilast, Methotrexate - Psoriasis
Phase 2 / Phase 3CompletedCairo University302023-01-092023-05-16
Clinical Study Evaluating the Safety and Efficacy of Roflumilast in Type 2 Diabetic Patients With Diabetic Neuropathy
Alpha lipoic acid, Roflumilast - Type 2 Diabetes (Adult Onset), Diabetic Neuropathies
Phase 3CompletedTanta University602022-08-012023-11-22
A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR)
CHF6001 1600µg, CHF6001 3200µg, Placebo - Chronic Obstructive Pulmonary Disease
Phase 3TerminatedChiesi Farmaceutici S.p.A.39732021-07-122026-02-02
The Possible Effects of Roflumilast on Obesity Related Disorders
Roflumilast, placebo - Obesity, PreDiabetes
Phase 3CompletedTanta University662021-05-012022-04-05
Possible Role of Roflumilast in Diabetic Nephropathy
Roflumilast, Placebo - Diabetic Nephropathies
Phase 3UnknownTanta University482021-03-102021-02-16
Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis
ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05% - Atopic Dermatitis Eczema
Phase 3CompletedArcutis Biotherapeutics, Inc.12202021-02-252025-12-23
Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis
Topical roflumilast - Chronic Plaque Psoriasis
Phase 3CompletedArcutis Biotherapeutics, Inc.3372020-02-122026-09-09
Roflumilast or Azithromycin to Prevent COPD Exacerbations Trial
Roflumilast, Azithromycin - Chronic Obstructive Pulmonary Disease Severe, Chronic Bronchitis
Phase 3CompletedJohns Hopkins University10322020-02-112026-08-21
Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis
Roflumilast 0.3% cream, Vehicle Cream - Chronic Plaque Psoriasis
Phase 3CompletedArcutis Biotherapeutics, Inc.4392019-12-202022-12-07
Efficacy of Roflumilast on Exacerbations in Patients With Non-cystic Fibrosis Bronchiectasis
Roflumilast, Placebo - Exacerbation Copd, Bronchiectasis
Phase 3CompletedPrince of Songkla University402015-01-012019-10-10
Enhancement of Corticosteroid Efficacy in COPD
Theophylline, Roflumilast - COPD
Phase 3CompletedUConn Health132014-12-012018-06-19
Evaluation of Tolerability and Pharmacokinetics of Roflumilast, 250μg and 500μg, as add-on to Standard COPD Treatment to Treat Severe COPD
Roflumilast, Roflumilast Placebo, Standard of Care COPD Treatment - Chronic Obstructive Pulmonary Disease (COPD)
Phase 3CompletedAstraZeneca13232014-05-012017-04-20
Effects of Roflumilast in Hospitalized Chronic Obstructive Pulmonary Disease( COPD) on Mortality and Re-hospitalization
Roflumilast, Placebo - COPD
Phase 3CompletedTemple University682013-11-012020-03-12
Trial to Assess the Anti-inflammatory Effects of Roflumilast in Chronic Obstructive Pulmonary Disease
Roflumilast, Placebo - COPD, Chronic Obstructive Pulmonary Disease
Phase 3CompletedAstraZeneca1582012-02-012019-11-29
A Chronic Obstructive Pulmonary Disease (COPD) Trial Investigating Roflumilast on Safety and Effectiveness in China, Hong Kong and Singapore:
Roflumilast, Placebo, Salbutamol - COPD
Phase 3CompletedAstraZeneca6262011-03-012017-02-01
Effect of Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Tiotropium: The HELIOS Study (BY217/M2-128)
Roflumilast, Placebo - Chronic Obstructive Pulmonary Disease
Phase 3CompletedAstraZeneca7432007-01-012016-12-05
Effect of Roflumilast on Lung Function in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Salmeterol: The EOS Study (BY217/M2-127)
Roflumilast, Placebo - Chronic Obstructive Pulmonary Disease (COPD)
Phase 3CompletedAstraZeneca9332006-04-012016-12-14
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The HERMES Study (BY217/M2-125)
Roflumilast, Placebo - Chronic Obstructive Pulmonary Disease (COPD)
Phase 3CompletedAstraZeneca15682006-03-012016-11-07

Showing 20 of 34. Sign in to see all of them.

Conditions studied

Pulmonary Disease, Chronic Obstructive (18)  ·  Asthma (6)  ·  Bronchitis, Chronic (2)  ·  Bronchiectasis (1)  ·  Depressive Disorder, Major (1)  ·  Diabetes Mellitus (1)  ·  Diabetes Mellitus, Type 2 (1)  ·  Diabetic Nephropathies (1)  ·  Diabetic Neuropathies (1)  ·  Emphysema (1)  ·  Hyperglycemia (1)  ·  Non-alcoholic Fatty Liver Disease (1)  ·  Obesity (1)  ·  Prediabetic State (1)  ·  Psoriasis (1)

Sponsors

AstraZeneca (20)  ·  Tanta University (5)  ·  Arcutis Biotherapeutics, Inc. (3)  ·  Cairo University (1)  ·  Chiesi Farmaceutici S.p.A. (1)  ·  Johns Hopkins University (1)  ·  Prince of Songkla University (1)  ·  Temple University (1)  ·  UConn Health (1)

Countries

United States (15)  ·  Canada (9)  ·  France (8)  ·  Spain (8)  ·  United Kingdom (8)  ·  Germany (7)  ·  Poland (7)  ·  South Africa (7)  ·  Austria (6)  ·  Egypt (5)  ·  Hungary (5)  ·  Italy (5)  ·  Russia (5)  ·  Japan (4)  ·  Argentina (3)

Top investigators

David Berk, MD (2)  ·  Gerard J Criner, MD (1)  ·  Hisham M Elnahhas, Pharm D (1)  ·  Jerry Krishnan, MD, PhD (1)  ·  Kanung Saejiam, MS (1)  ·  Mostafa Bahaa (1)  ·  Nausherwan Burki (1)  ·  Robert Wise, MD (1)  ·  Sara M Zayed (1)

Results publications

PMID 20102307, PMID 28419462, PMID 26498386, PMID 26612545, PMID 19716960, PMID 19716961, PMID 21272339, PMID 23117188, PMID 24120253, PMID 24135893, PMID 26456372, PMID 29797235, PMID 30224319, PMID 36125472, PMID 36422852, PMID 41134450, PMID 41256904

NIH funding

2005 (1), 2023 (1)